Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Favipiravir (meta) Sotrovimab (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Melatonin (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 66% Improvement Relative Risk Case 9% c19hcq.com/patil.html Favors HCQ Favors control
24 August 2021 - Pre-Exposure Prophylaxis study (treated before exposed to the virus)
A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19 in Autoimmune Rheumatic Diseases
Patil et al., Research Square, doi:10.21203/rs.3.rs-805748/v1 (Preprint)
Source   PDF   Share   Tweet
Prospective study of 9,212 autoimmune rheumatic disease patients showing lower mortality with HCQ, without reaching statistical significance. Authors incorrectly state "HCQ use did not influence occurrence of COVID-19 (RR = 0.909, CI (0.715,1.154), p = 0.432) or mortality (p = 0.097)" [1]. CFR for the autoimmune rheumatic disease patients was 4.6 times higher than in the general population from the same area.
risk of death, 65.9% lower, RR 0.34, p = 0.10, treatment 5,266, control 3,946.
risk of case, 9.1% lower, RR 0.91, p = 0.43, treatment 167 of 5,266 (3.2%), control 147 of 3,946 (3.7%), NNT 181, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Patil et al., 8/24/2021, prospective, India, South Asia, preprint, 20 authors.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit